胰激肽原酶联合普瑞巴林治疗痛性糖尿病周围神经病变的临床效果

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (40 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the effect and safety of Pancreatic Kininogenase combined with Pregabalin in the treatment of painful diabetic peripheral neuropathy (PDPN). Methods From January to December 2017, 68 patients with PDPN treated in the Endocrinology Department of Hubei Provincial Hospital of Integrated Chinese and Western Medicine were selected as the research subjects, and they were divided into the control group and the treatment group by the random number table method, with 34 cases in each group. The patients in the two groups were given basic medical treatment such as blood glucose control. On the basis of this, the control group was treated with Pregabalin and the treatment group was treated with Pancreatic Kininogenase and Pregabalin for 8 weeks. Visual analogue scale (VAS)was used to evaluate the pain intensity changes between the two groups before and after treatment. Sensory nerve conduction velocity (SNCV) and motor nerve conduction velocity (MNCV) were measured and compared between the two groups. The incidence of adverse drug reactions was recorded. Results There was no statistically significant difference in the VAS score between the two groups before treatment (P＞0.05). After treatment, the VAS scores in the two groups were lower than those in the same group before treatment, the differences were statistically significant (P＜0.05), and the VAS score in the treatment group after treatment was lower than that in the control group, the difference was statistically significant (P＜0.05). There was no significant difference in the SNCV before treatment between the two groups (P＞0.05). The SNCV after treatment in the two groups was higher than that in the same group before treatment, and the difference was statistically significant (P＜0.05). And the SNCV after treatment in the treatment group was higher than that in the control group, the difference was statistically significant (P＜0.05). There was no significant difference in MNCV before treatment between the two groups (P＞0.05). The MNCV after treatment in the treatment group was higher than that in the same group before treatment, and the difference was statistically significant (P＜0.05). There was no significant difference in MNCV between the control group before and after treatment (P＞0.05). The MNCV after treatment in the treatment group was higher than that in the control group, with statistically significant difference (P＜0.05). There was no significant difference in the total incidence rate of adverse reactions between the two groups (P＞0.05). Conclusion Pancreatic Kininogenase combined with Pregabalin has a better effect on pain improvement than Pregabalin alone in the treatment of PDPN. At the same time, it can improve the SNCV and MNCV of patients. The effect is better than that of Pregabalin alone, and it is safe for clinical application.

Key words： Diabetic peripheral neuropathy Neuralgia Pancreatic Kininogenase Pregabalin

Received: 03 March 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I29/4

[1]	Ummer VS，Maiya AG，Hande，M，et al.Low level laser therapy for the patients with painful diabetic peripheral neuropathy-A systematic review[J].Diabetes Metab Syndr，2019，13（4）：2667-2670.
[2]	李莹，冷锦红.痛性糖尿病周围神经病变发病机制研究进展[J].辽宁中医药大学学报，2019，19（11）：117-121.
[3]	孙蕾，姚娟，李群琳，等.普瑞巴林在慢性疼痛治疗中的应用[J].中国现代医生，2018，56（8）：116-118.
[4]	韩方义.胰激肽原酶联合西洛他唑与α-硫辛酸治疗糖尿病周围神经病变的临床研究[J].中西医结合心脑血管病杂志，2019，17（16）：2542-2545.
[5]	Gabir MM，Hanson RL，Dabelea D，et al.The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes[J].Diabetes Care，2000，23（8）：1108-1112.
[6]	《临床医学研究与实践》编辑部.糖尿病性周围神经病理性疼痛诊疗专家共识[J].临床医学研究与实践，2018，3（27）：封3.
[7]	Javed S，Hayat T，Menon L，et al.Diabetic peripheral neuropathy in people with type 2 diabetes：too little too late[J].Diabet Med，2020，37（4）：573-579.
[8]	Reich A，Heisig M，Phan NQ，et al.Visual analogue scale：evaluation of the instrument for the assessment of pruritus[J].Acta Derm Venereol，2012，92（5）：497-501.
[9]	宋欢欢，杨赞，周建国，等.影响无症状糖尿病周围神经病变神经传导速度的相关因素分析[J].中风与神经疾病杂志，2019，36（8）：735-738.
[10]	Selvarajah D，Kar D，Khunti K，et al.Diabetic peripheral neuropathy：advances in diagnosis and strategies for screening and early intervention[J].Lancet Diabetes Endocrinol，2019，7（12）：938-948.
[11]	Schreiber AK，Nones CF，Reis RC，et al.Diabetic neuropathic pain：Physiopathology and treatment[J].World J Diabetes，2015，6（3）：432-444.
[12]	章晓燕，刘芳.痛性糖尿病周围神经病变的药物治疗进展[J].中华糖尿病杂志，2015，7（11）：709-711.
[13]	Freeman R，Durso-Decruz E，Emir B.Efficacy，safety，and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy：findings from seven randomized，controlled trials across a range of doses[J].Diabetes Care，2008，31（7）：1448-1454.
[14]	Parsons B，Li C.The efficacy of pregabalin in patients with moderate and severe pain due to diabetic peripheral neuropathy[J].Curr Med Res Opin，2016，32（5）：929-937.
[15]	Parsons B，Li C，Emir B，et al.The efficacy of pregabalin for treating pain associated with diabetic peripheral neuropathy in subjects with type 1 or type 2 diabetes mellitus[J].Curr Med Res Opin，2018，34（11）：2015-2022.
[16]	Zhu D，Zhang L，Cheng L，et al.Pancreatic Kininogenase Ameliorates Renal Fibrosis in Streptozotocin Induced-Diabetic Nephropathy Rat[J].Kidney Blood Press Res，2016，41（1）：9-17.
[17]	Jin YP，Su XF，Li HQ，et al.The Therapeutic Effect of Pancreatic Kininogenase on Treatment of Diabetic Peripheral Neuropathy in Patients with Type 2 Diabetes[J].Exp Clin Endocrinol Diabetes，2016，124（10）：618-621.